15th Conference Clinical Trials Alzheimer’s Disease, November 29–December 2, 2022, San Francisco, CA, USA: Posters (Clinical Trial Alzheimer’s Disease)

placebo there was a positive trend for ISLT Immediate Recall [p=0.053, difference=+2.1 words (95% CI: -0.03, 4.17), Cohen’s d effect size=0.28] and a significant positive difference for ISLT recognition [p=0.024, difference=+1.4 words, 95%CI=0.2, 2.5, d=1.0)}.

also in 11,005 other papers

Logistic regression results showed a trend to significant interactions between sex and plasma GFAP (P=0.056) and plasma p-tau231 (P=0.099) for the prediction of CSF Aβ status.

also in 53,322 other papers

No difference was observed in Aβ42 or Aβ40 levels between groups, although the difference in Aβ42 levels between low and high overall burden of PVS was approaching significance (F(1,53) = 3.65 p = 0.064, η2 = .06).

also in 2,640 other papers

For the primary outcome measure (ADRI), persons in the CS group showed larger increases than those in the TAU group, and although the difference did not reach statistical significance (t = 1.72, p = 0.11) it represented a large effect size (d > 1.00).

also in 111,027 other papers

Here we present results from additional executive functioning tests (One Touch Stockings, Spatial Working Memory, and 2-Back tests) showing improvement from baseline at Day 14, noting that an overall trend of improved performance from baseline at Day 14 was observed across all tests of executive functioning.

also in 4,871 other papers